KPJ Healthcare Berhad Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

KPJ Healthcare Berhad wird ein jährliches Gewinn- und Umsatzwachstum von 6.3% bzw. 6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.2% betragen.

Wichtige Informationen

6.8%

Wachstumsrate der Gewinne

4.5%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	1.4%
Wachstumsrate der Einnahmen	5.7%
Zukünftige Eigenkapitalrendite	12.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

KPJ Healthcare Berhad's (KLSE:KPJ) Dividend Will Be MYR0.01

Jun 02

Here's Why KPJ Healthcare Berhad (KLSE:KPJ) Has Caught The Eye Of Investors

Mar 25

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

Mar 11

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 31% Above Its Share Price

Jun 06

These 4 Measures Indicate That KPJ Healthcare Berhad (KLSE:KPJ) Is Using Debt Reasonably Well

May 03

KPJ Healthcare Berhad (KLSE:KPJ) Has More To Do To Multiply In Value Going Forward

Mar 07

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 20

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

KPJ Healthcare Berhad (KLSE:KPJ) Is Increasing Its Dividend To MYR0.0055

Sep 15

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 01

Capital Allocation Trends At KPJ Healthcare Berhad (KLSE:KPJ) Aren't Ideal

Aug 11

The Consensus EPS Estimates For KPJ Healthcare Berhad (KLSE:KPJ) Just Fell Dramatically

May 30

Does KPJ Healthcare Berhad (KLSE:KPJ) Have A Place In Your Dividend Stock Portfolio?

Apr 09

KPJ Healthcare Berhad (KLSE:KPJ) Takes On Some Risk With Its Use Of Debt

Mar 25

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 46% Below Their Intrinsic Value Estimate

Mar 10

Analyst Forecasts Just Became More Bearish On KPJ Healthcare Berhad (KLSE:KPJ)

Feb 23

Gewinn- und Umsatzwachstumsprognosen

KLSE:KPJ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (MYR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4,114	360	599	736	9
12/31/2025	3,825	324	472	721	13
12/31/2024	3,625	292	431	742	13
3/31/2024	3,512	303	350	591	N/A
12/31/2023	3,419	281	417	658	N/A
9/30/2023	3,269	271	364	583	N/A
6/30/2023	3,142	231	324	548	N/A
3/31/2023	3,042	211	282	527	N/A
12/31/2022	2,868	179	226	460	N/A
9/30/2022	2,792	122	284	555	N/A
6/30/2022	2,692	84	250	485	N/A
3/31/2022	2,626	64	225	470	N/A
12/31/2021	2,590	55	195	412	N/A
9/30/2021	2,560	58	122	368	N/A
6/30/2021	2,495	79	128	386	N/A
3/31/2021	2,338	85	93	307	N/A
12/31/2020	2,397	110	95	337	N/A
9/30/2020	1,853	169	160	415	N/A
6/30/2020	2,138	182	110	446	N/A
3/31/2020	2,523	211	132	535	N/A
12/31/2019	2,738	211	177	581	N/A
9/30/2019	3,581	180	148	604	N/A
6/30/2019	3,483	176	167	560	N/A
3/31/2019	3,424	176	174	543	N/A
12/31/2018	3,366	179	131	518	N/A
9/30/2018	3,279	188	3	381	N/A
6/30/2018	3,246	177	-81	296	N/A
3/31/2018	3,224	168	-84	359	N/A
12/31/2017	3,180	166	N/A	362	N/A
9/30/2017	3,040	161	N/A	279	N/A
6/30/2017	3,018	162	N/A	391	N/A
3/31/2017	3,005	160	N/A	239	N/A
12/31/2016	2,970	154	N/A	143	N/A
9/30/2016	2,978	124	N/A	187	N/A
6/30/2016	2,933	130	N/A	115	N/A
3/31/2016	2,882	136	N/A	192	N/A
12/31/2015	2,848	135	N/A	189	N/A
9/30/2015	2,862	158	N/A	338	N/A
6/30/2015	2,798	149	N/A	322	N/A
3/31/2015	2,746	147	N/A	339	N/A
12/31/2014	2,639	143	N/A	319	N/A
9/30/2014	2,556	126	N/A	270	N/A
6/30/2014	2,464	117	N/A	174	N/A
3/31/2014	2,389	108	N/A	140	N/A
12/31/2013	2,332	103	N/A	144	N/A
9/30/2013	2,209	108	N/A	138	N/A
6/30/2013	2,174	122	N/A	170	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KPJDas prognostizierte Gewinnwachstum (6.3% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: KPJDie Erträge des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt MY (11.8% pro Jahr).

Hohe Wachstumserträge: KPJDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: KPJDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt MY (6% pro Jahr).

Hohe Wachstumseinnahmen: KPJDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: KPJDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.2%).

KPJ Healthcare Berhad Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.4% to RM1.93

Price target increased by 8.3% to RM1.72

Price target increased by 8.6% to RM1.48

Consensus EPS estimates increase by 25%

Price target increased by 8.7% to RM1.23

Consensus EPS estimates increase by 30%

Recent updates

Price target increased by 7.4% to RM1.93

KPJ Healthcare Berhad Appoints Encik Mohd Khairul Izzad Bin Mohammed Shamsudin as Chief Financial Officer, Effective June 10, 2024

KPJ Healthcare Berhad's (KLSE:KPJ) Dividend Will Be MYR0.01

First quarter dividend of RM0.01 announced

First quarter 2024 earnings: EPS misses analyst expectations

KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2024

Here's Why KPJ Healthcare Berhad (KLSE:KPJ) Has Caught The Eye Of Investors

KPJ Healthcare Berhad Announces Resignation of Md Arif Bin Mahmood as Non Independent and Non Executive Chairman, Effective April 1, 2024

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

Price target increased by 8.3% to RM1.72

Full year 2023 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad's (KLSE:KPJ) Shares May Have Run Too Fast Too Soon

Is KPJ Healthcare Berhad (KLSE:KPJ) Using Too Much Debt?

Returns At KPJ Healthcare Berhad (KLSE:KPJ) Appear To Be Weighed Down

Upcoming dividend of RM0.013 per share at 3.0% yield

Price target increased by 8.6% to RM1.48

KPJ Healthcare Berhad to Report Q3, 2023 Results on Nov 28, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Special Dividend for the Financial Year Ending 31 December 2023

KPJ Healthcare Berhad Announces Appointment of Keh Ching Tyng as Joint Secretary

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kpj Healthcare Berhad Announces Appointment of Mr. Chin Keat Chyuan as President, Effective 1 September 2023

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 31% Above Its Share Price

KPJ Healthcare Berhad Declares Interim Dividend for the Year Ended December 31, 2023, Payable on July 4, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued

These 4 Measures Indicate That KPJ Healthcare Berhad (KLSE:KPJ) Is Using Debt Reasonably Well

Full year 2022 earnings released: EPS: RM0.04 (vs RM0.013 in FY 2021)

Now 23% undervalued

Now 22% undervalued

Now 21% undervalued

KPJ Healthcare Berhad (KLSE:KPJ) Has More To Do To Multiply In Value Going Forward

Consensus EPS estimates increase by 25%

Price target increased by 8.7% to RM1.23

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year End December 31, 2023, Payable on April 14, 2023

Now 21% undervalued

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 26% Above Its Share Price

Upcoming dividend of RM0.01 per share

Consensus EPS estimates increase by 30%

Price target increased to RM1.07

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year Ended December 31, 2022, Payable on December 28, 2022

KPJ Healthcare Berhad (KLSE:KPJ) Is Increasing Its Dividend To MYR0.0055

KPJ Healthcare Berhad Appoints Encik Hisham Bin Zainal Mokhtar as Independent and Non Executive Member of Risk Committee

KPJ Healthcare Berhad Announces Resignation of Mohd Shukrie Bin Mohd Salleh as Managing Director

KPJ Healthcare Berhad Announces Resignation of Mohd Shukrie Bin Mohd Salleh as Managing Director

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Fiscal Year Ending December 31, 2022, Payable on 21 October 2022

KPJ Healthcare Berhad Announces the Resignation of TEH PENG PENG as Joint Secretary

KPJ Healthcare Berhad Appoints Nantha Kumar Subramanian as Its New Chief Digital Officer

KPJ Healthcare Berhad Appoints Lee Lai Fan as Independent and Non Executive Director

KPJ Healthcare Berhad Announces Retirement of Puan Lydia Anne Abraham as Independent and Non Executive Director

Consensus EPS estimates fall by 17%

High number of new directors

Now 22% undervalued after recent price drop

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year Ending December 31, 2022, Payable on 29 Jul 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

KPJ Healthcare Berhad, Annual General Meeting, Jun 28, 2022

Now 20% undervalued after recent price drop

KPJ Healthcare Berhad Appoints Dato' Mohd Redza Shah Bin Abdul Wahid as Chairman of Nomination and Remuneration Committee and Independent and Non Executive, Effective from April 1, 2022

Now 22% undervalued after recent price drop

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year End December 31, 2022, Payable on April 22, 2022

Now 20% undervalued